Investors should be cautious due to the company's significant net losses, Nasdaq compliance history, and internal control weaknesses. While the $11M funding provides near-term capital, the company's path to profitability is uncertain given its early stage of development and lack of approved products.
Executive Summary
Aspire Biopharma is a clinical-stage biopharmaceutical company developing a high-dose sublingual aspirin for heart attack/stroke treatment. It recently raised $11M through a convertible preferred stock offering, but faces significant financial and regulatory risks including a history of net losses, Nasdaq compliance issues, and material weaknesses in internal controls.
Key Facts
- Raised $11M from convertible preferred stock offering (First Tranche) with $943,801 of debt converted
- Has not yet generated revenue from product sales; reported $6,202 in revenue from nutraceutical products in 2025
- Incurred net losses of $24.5M in 2025, up from $1.3M in 2024
- Company was delisted from Nasdaq Global Market but regained compliance with Bid Price Rule and moved to Nasdaq Capital Market
- Management identified material weaknesses in internal control over financial reporting
- Lead product candidate is high-dose sublingual aspirin currently in clinical development
Financial Impact
Raised $11M in gross proceeds from convertible preferred stock offering
Risk Factors
- Continuing net losses and need for substantial additional financing
- Regulatory risks related to FDA approval of lead product candidate
- Dilution risk from convertible securities and equity line of credit agreements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001493152-26-016123 |
| Exhibit: ex23-2.htm | 0001493152-26-016123 |
| Exhibit: ex23-1.htm | 0001493152-26-016123 |
| Document: 0001493152-26-016123-index-headers.html | 0001493152-26-016123 |
| Document: 0001493152-26-016123-index.html | 0001493152-26-016123 |
| Document: 0001493152-26-016123.txt | 0001493152-26-016123 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 20, 2026 27w ago | 8-K | $0.0200 $0.0243 | ▲ +21.50% | ▲ +14.72% | — |
Apr 16, 2026 27w ago | 8-K | $0.0200 $0.0200 | · 0.00% | ▼ −6.14% | — |
Apr 16, 2026 27w ago | 8-K | $0.0200 $0.0239 | ▲ +19.50% | ▲ +12.45% | — |
Apr 15, 2026 27w ago | EFFECT | $0.0200 $0.0200 | · 0.00% | ▼ −8.14% | — |
Apr 10, 2026 28w ago | S-1/A | $0.0200 $0.0200 | · 0.00% | ▲ +10.33% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers